Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

'Fast Money' traders talk GLP-1 manufacturer stocks sinking on uncertainty and price negotiation. These are the most ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...